Publications by authors named "G MAGGIONI"
Hidradenocarcinoma (HAC) is a rare malignant neoplasm originating from eccrine sweat glands, often presenting diagnostic challenges because of its resemblance to other malignancies, particularly breast cancer when occurring in the chest region. This report describes 2 cases of HAC with axillary lymph node metastasis, both initially misinterpreted clinically. The first case involved a 63-year-old woman with a sternal mass, near the right breast, initially suspected to be a sebaceous cyst.
View Article and Find Full Text PDFArticle Synopsis
- The WHO and International Consensus Classification 2022 aim to improve diagnosis and treatment decisions for myelodysplastic syndromes, but disparities in their implementation exist.
- A panel of experts used a data-driven method and the Delphi consensus process to align the two classifications, focusing on genomic features to create harmonized labels for distinct clusters.
- Key findings identified nine genomic clusters, with the most significant linked to biallelic TP53 inactivation, and highlighted the inadequacy of traditional morphological assessments in capturing the complexity of these diseases.
Background: Psychopathological disorders are often comorbid diagnosis in eating disorders (EDs). We aimed to assess the presence of psychopathological traits and symptoms associated with EDs in an Italian high school adolescent population.
Methods: A sample of high school adolescents was enrolled, and demographic and clinical data were collected.
Purpose: Rare cancers constitute over 20% of human neoplasms, often affecting patients with unmet medical needs. The development of effective classification and prognostication systems is crucial to improve the decision-making process and drive innovative treatment strategies. We have created and implemented MOSAIC, an artificial intelligence (AI)-based framework designed for multimodal analysis, classification, and personalized prognostic assessment in rare cancers.
View Article and Find Full Text PDFClinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes.
J Clin Oncol
August 2024
Article Synopsis
- Allogeneic hematopoietic stem-cell transplantation is the only curative option for patients with myelodysplastic syndromes, and the timing of this treatment is crucial for maximizing benefits and minimizing risks.
- A decision support system was developed to identify the optimal timing for HSCT based on clinical and genomic data from a large study of over 7,000 patients, comparing outcomes using the Molecular International Prognostic Scoring System (IPSS-M) against traditional scoring methods.
- The findings suggest that patients with lower risk can benefit from delaying transplantation, while those at higher risk should undergo it immediately, indicating that the IPSS-M strategy significantly improves life expectancy and supports personalized treatment plans.